FDA Fast-tracks the First Inhalable Gene Therapy for Cancer
Early clinical findings have led the FDA to grant RMAT designation to a first-of-its-kind inhalable gene therapy being developed for
Read more
Oncology
Breakthroughs in Cervical Cancer Research Using Cellendes’ Advanced 3-D Life Hydrogel Products
A research study has showcased the use of Cellendes’ advanced 3-D Life Hydrogel products in developing an immunocompetent, PDMS-free organ-on-chip
Read more
AstraZeneca Acquires Modella AI to Expand Oncology AI Capabilities
AstraZeneca has acquired Modella AI, as announced by the Boston-based artificial intelligence company on Tuesday. Focused on life sciences, the
Read more
Merck’s KEYTRUDA QLEX™ Secures FDA Approval as First Subcutaneous Pembrolizumab Injection
Merck & Co., known as MSD outside of the United States and Canada, announced on Saturday that the U.S. Food
Read more
FDA Approves J&J’s Inlexzo™ Breakthrough Bladder Cancer Therapy
Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved INLEXZO™ (gemcitabine intravesical system), a
Read more
Boehringer’s HERNEXEOS® Wins Accelerated FDA Nod in Lung Cancer
In a landmark decision for HER2-mutant lung cancer, the US FDA has granted accelerated approval to Boehringer Ingelheim’s HERNEXEOS® (zongertinib),
Read more
Lilly’s Jaypirca Outperforms Imbruvica in CLL Head-to-Head Phase 3 Trial
Eli Lilly’s Jaypirca (pirtobrutinib), the first and only FDA-approved non-covalent (reversible) BTK inhibitor, has met its primary endpoint in the
Read more
GSK Bolsters Gastrointestinal Cancer Portfolio with $1.15B Acquisition of IDRx
In a strategic move to expand its oncology pipeline, GSK plc (LSE/NYSE: GSK) announced on Tuesday, it has entered into
Read more
AstraZeneca Unveils $300 Million Cell Therapy Manufacturing Facility in Rockville, USA
Global biopharmaceutical leader AstraZeneca has officially opened a new $300 million state-of-the-art cell therapy manufacturing facility in Rockville, Maryland, marking
Read more
Merck KGaA Agrees to Acquire SpringWorks for $3.9 Billion
Merck KGaA is moving forward with the acquisition of SpringWorks Therapeutics, confirming a definitive agreement at $47 per share in
Read more